P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth

Xiaokun Gang, Yinhui Yang, Jian Zhong, Kui Jiang, Yunqian Pan, Robert Jeffrey Karnes, Jun Zhang, Wanhai Xu, Guixia Wang, Haojie Huang

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

De novo fatty acid (FA) synthesis is required for prostate cancer (PCa) survival and progression. As a key enzyme for FA synthesis fatty acid synthase (FASN) is often overexpressed in human prostate cancers and its expression correlates with worse prognosis and poor survival. P300 is an acetyltransferase that acts as a transcription co-activator. Increasing evidence suggests that P300 is a major PCa promoter, although the underlying mechanism remains poorly understood. Here, we demonstrated that P300 binds to and increases histone H3 lysine 27 acetylation (H3K27Ac) in the FASN gene promoter. We provided evidence that P300 transcriptionally upregulates FASN expression and promotes lipid accumulation in human PCa cells in culture and Pten knockout prostate tumors in mice. Pharmacological inhibition of P300 decreased FASN expression and lipid droplet accumulation in PCa cells. Immunohistochemistry analysis revealed that expression of P300 protein positively correlates with FASN protein levels in a cohort of human PCa specimens. We further showed that FASN is a key mediator of P300-induced growth of PCa cells in culture and in mice. Together, our findings demonstrate P300 as a key factor that regulates FASN expression, lipid accumulation and cell growth in PCa. They also suggest that this regulatory pathway can serve as a new therapeutic target for PCa treatment.

Original languageEnglish (US)
Pages (from-to)15135-15149
Number of pages15
JournalOncotarget
Volume7
Issue number12
DOIs
StatePublished - Mar 22 2016

Fingerprint

Fatty Acid Synthases
Lipid Metabolism
Prostatic Neoplasms
Growth
Fatty Acids
Cell Culture Techniques
Lipids
p300-CBP-associated factor
Survival
Acetylation
Histones
Lysine
Prostate
Proteins
Up-Regulation
Immunohistochemistry
Pharmacology

Keywords

  • FASN
  • Histone acetylation
  • Lipid metabolism
  • P300
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. / Gang, Xiaokun; Yang, Yinhui; Zhong, Jian; Jiang, Kui; Pan, Yunqian; Karnes, Robert Jeffrey; Zhang, Jun; Xu, Wanhai; Wang, Guixia; Huang, Haojie.

In: Oncotarget, Vol. 7, No. 12, 22.03.2016, p. 15135-15149.

Research output: Contribution to journalArticle

Gang, Xiaokun ; Yang, Yinhui ; Zhong, Jian ; Jiang, Kui ; Pan, Yunqian ; Karnes, Robert Jeffrey ; Zhang, Jun ; Xu, Wanhai ; Wang, Guixia ; Huang, Haojie. / P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. In: Oncotarget. 2016 ; Vol. 7, No. 12. pp. 15135-15149.
@article{c6eee9700ca4473287c3ae157d9162fa,
title = "P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth",
abstract = "De novo fatty acid (FA) synthesis is required for prostate cancer (PCa) survival and progression. As a key enzyme for FA synthesis fatty acid synthase (FASN) is often overexpressed in human prostate cancers and its expression correlates with worse prognosis and poor survival. P300 is an acetyltransferase that acts as a transcription co-activator. Increasing evidence suggests that P300 is a major PCa promoter, although the underlying mechanism remains poorly understood. Here, we demonstrated that P300 binds to and increases histone H3 lysine 27 acetylation (H3K27Ac) in the FASN gene promoter. We provided evidence that P300 transcriptionally upregulates FASN expression and promotes lipid accumulation in human PCa cells in culture and Pten knockout prostate tumors in mice. Pharmacological inhibition of P300 decreased FASN expression and lipid droplet accumulation in PCa cells. Immunohistochemistry analysis revealed that expression of P300 protein positively correlates with FASN protein levels in a cohort of human PCa specimens. We further showed that FASN is a key mediator of P300-induced growth of PCa cells in culture and in mice. Together, our findings demonstrate P300 as a key factor that regulates FASN expression, lipid accumulation and cell growth in PCa. They also suggest that this regulatory pathway can serve as a new therapeutic target for PCa treatment.",
keywords = "FASN, Histone acetylation, Lipid metabolism, P300, Prostate cancer",
author = "Xiaokun Gang and Yinhui Yang and Jian Zhong and Kui Jiang and Yunqian Pan and Karnes, {Robert Jeffrey} and Jun Zhang and Wanhai Xu and Guixia Wang and Haojie Huang",
year = "2016",
month = "3",
day = "22",
doi = "10.18632/oncotarget.7715",
language = "English (US)",
volume = "7",
pages = "15135--15149",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

TY - JOUR

T1 - P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth

AU - Gang, Xiaokun

AU - Yang, Yinhui

AU - Zhong, Jian

AU - Jiang, Kui

AU - Pan, Yunqian

AU - Karnes, Robert Jeffrey

AU - Zhang, Jun

AU - Xu, Wanhai

AU - Wang, Guixia

AU - Huang, Haojie

PY - 2016/3/22

Y1 - 2016/3/22

N2 - De novo fatty acid (FA) synthesis is required for prostate cancer (PCa) survival and progression. As a key enzyme for FA synthesis fatty acid synthase (FASN) is often overexpressed in human prostate cancers and its expression correlates with worse prognosis and poor survival. P300 is an acetyltransferase that acts as a transcription co-activator. Increasing evidence suggests that P300 is a major PCa promoter, although the underlying mechanism remains poorly understood. Here, we demonstrated that P300 binds to and increases histone H3 lysine 27 acetylation (H3K27Ac) in the FASN gene promoter. We provided evidence that P300 transcriptionally upregulates FASN expression and promotes lipid accumulation in human PCa cells in culture and Pten knockout prostate tumors in mice. Pharmacological inhibition of P300 decreased FASN expression and lipid droplet accumulation in PCa cells. Immunohistochemistry analysis revealed that expression of P300 protein positively correlates with FASN protein levels in a cohort of human PCa specimens. We further showed that FASN is a key mediator of P300-induced growth of PCa cells in culture and in mice. Together, our findings demonstrate P300 as a key factor that regulates FASN expression, lipid accumulation and cell growth in PCa. They also suggest that this regulatory pathway can serve as a new therapeutic target for PCa treatment.

AB - De novo fatty acid (FA) synthesis is required for prostate cancer (PCa) survival and progression. As a key enzyme for FA synthesis fatty acid synthase (FASN) is often overexpressed in human prostate cancers and its expression correlates with worse prognosis and poor survival. P300 is an acetyltransferase that acts as a transcription co-activator. Increasing evidence suggests that P300 is a major PCa promoter, although the underlying mechanism remains poorly understood. Here, we demonstrated that P300 binds to and increases histone H3 lysine 27 acetylation (H3K27Ac) in the FASN gene promoter. We provided evidence that P300 transcriptionally upregulates FASN expression and promotes lipid accumulation in human PCa cells in culture and Pten knockout prostate tumors in mice. Pharmacological inhibition of P300 decreased FASN expression and lipid droplet accumulation in PCa cells. Immunohistochemistry analysis revealed that expression of P300 protein positively correlates with FASN protein levels in a cohort of human PCa specimens. We further showed that FASN is a key mediator of P300-induced growth of PCa cells in culture and in mice. Together, our findings demonstrate P300 as a key factor that regulates FASN expression, lipid accumulation and cell growth in PCa. They also suggest that this regulatory pathway can serve as a new therapeutic target for PCa treatment.

KW - FASN

KW - Histone acetylation

KW - Lipid metabolism

KW - P300

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84962844387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962844387&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7715

DO - 10.18632/oncotarget.7715

M3 - Article

C2 - 26934656

AN - SCOPUS:84962844387

VL - 7

SP - 15135

EP - 15149

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -